Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Raymond

Showing results (81-90 of 173) with videos related to

Pageof 18
Sort By:
Journal of Neuro-Oncology|January 9, 2015
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomasStéphane Goutagny, Eric Raymond, Marina Esposito-Farese, et al.
Marine Drugs|March 23, 2013
Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compoundMaria Serova, Armand de Gramont, Ivan Bieche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2004
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancerEric Raymond, Jérôme Alexandre, Sandrine Faivre, et al.
The Oncologist|March 22, 2014
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenibMaxime Ronot, Mohamed Bouattour, Johanna Wassermann, et al.
Annales De Biologie Clinique|February 23, 2024
Management of unexpected laboratory exposure to Burkholderia pseudomalleiImane Mostaghat, Carine Couzigou, Benoît Pilmis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunctionEric Raymond, Valérie Boige, Sandrine Faivre, et al.
Oral Oncology|January 9, 2019
Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapyDiane Evrard, Petr Szturz, Annemilaï Tijeras-Raballand, et al.
Neuroendocrinology|June 13, 2009
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumorsFrédérique Maire, Pascal Hammel, Sandrine Faivre, et al.
International Journal of Oncology|July 13, 2005
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanismsAnne-Marie Coudray, Christophe Louvet, Michel Kornprobst, et al.
Head & Neck|February 9, 2005
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neckSandrine Faivre, Adina Marti, Olivier Rixe, et al.
Pageof 18

Showing results (81-90 of 173) with videos related to

Sort By:
Pageof 18
Journal of Neuro-Oncology|January 9, 2015
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomasStéphane Goutagny, Eric Raymond, Marina Esposito-Farese, et al.
Marine Drugs|March 23, 2013
Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compoundMaria Serova, Armand de Gramont, Ivan Bieche, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2004
Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancerEric Raymond, Jérôme Alexandre, Sandrine Faivre, et al.
The Oncologist|March 22, 2014
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenibMaxime Ronot, Mohamed Bouattour, Johanna Wassermann, et al.
Annales De Biologie Clinique|February 23, 2024
Management of unexpected laboratory exposure to Burkholderia pseudomalleiImane Mostaghat, Carine Couzigou, Benoît Pilmis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2002
Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunctionEric Raymond, Valérie Boige, Sandrine Faivre, et al.
Oral Oncology|January 9, 2019
Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapyDiane Evrard, Petr Szturz, Annemilaï Tijeras-Raballand, et al.
Neuroendocrinology|June 13, 2009
Temozolomide: a safe and effective treatment for malignant digestive endocrine tumorsFrédérique Maire, Pascal Hammel, Sandrine Faivre, et al.
International Journal of Oncology|July 13, 2005
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanismsAnne-Marie Coudray, Christophe Louvet, Michel Kornprobst, et al.
Head & Neck|February 9, 2005
Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neckSandrine Faivre, Adina Marti, Olivier Rixe, et al.
Pageof 18